Maintenance Therapy in AML Comes of Age: Presentation and Discussion

Recording:

Faculty :

• Andre Schuh, Princess Margaret Cancer Centre, University of Toronto, Toronto
• John Storring, McGill University Health Centre, Montreal
• Lynn Savoie, Tom Baker Cancer Centre, University of Calgary, Calgary

Objective:

While maintenance therapy has long been a standard of care in ALL and in APL, until recently there has been little evidence to support its use in non-APL AML. In this webinar we will review recent data that have led to the approval of oral azacitidine for AML maintenance, will define the optimal use of oral azacitidine for this indication, and will discuss the evolving role of maintenance therapy in FLT3-mutated AML.

Description:

A presentation and discussion of the history of, and a current approach to, maintenance therapy in AML, illustrated by patient cases

Some of the topics we will discuss include:

• how to identify candidates for maintenance therapy in AML
• what does ‘transplant ineligible’ actually mean?
• potential oral azacitidine toxicities, and how to deal with them
• how long should a patient stay on maintenance?
• what about post alloSCT maintenance?
• what’s on the horizon?